Go to content





Managing the Challenge of Ocular Inflamation - Steroids as a Powerful Tool

Lunch Symposium

Sponsored by : Bausch + Lomb


12:15 - 13:15

Hall 01

Managing the Challenge of Ocular Inflamation - Steroids as a Powerful Tool


Uwe Pleyer


Emrullah Tasindi, Piergiorgio Neri


Technical improvements in ocular surgery have led to rising patient expectations with regard to visual outcomesand tolerability. Adequate management of post-operative in ammation is a prerequisite for optimal surgical results. Corticosteroids are a mainstay of post-operative therapy due to their broad-spectrum and immediate anti-in ammatory e ect. In order to prevent exogenous endophthalmitis, a severe complication of surgery, steroids are often combined with antibiotics. The arsenal of anti-in ammatory drugs is augmented by NSAIDs, which are increasingly used in combination with steroids mainly to avoid post-operative cystoid macular oedema. Through their di erent targets in the in ammation cascade, steroids and NSAIDs are able to additively minimisein ammation. Within the symposium we will explore the current state of post-operative anti-in ammatory treatment.

The importance of using a steroid with an adequate efficacy and safety profilewill be addressed in the following. The ocular steroid loteprednol etabonate (LE) exhibits a favourable pharmacodynamic pro le, demonstrating a4.3 times increased potency compared to dexamethasone.Its unique ester structure enables it to penetrateeffectively into ocular tissues. LE is clinically active against all inflammatory conditions, including inflammationassociated with dry eye. 2- The ester structure of LE allows for its rapid one step deactivation, therapy producing and anti inflammatory effect with a lower propensity to elevate intraocular pressure compared with other steroids. 3- These properties make LE a clinically valuable, effective ocular steroid, especially in terms of long term treatment.

Druzgala P, et al. J Steroid Biochem Mol Biol 1991;38:149-54.
P ugfelder SC, et al. Am J Ophthalmol 2004;138:444-57.
Bartlett JD, et al. J Ocul Pharmacol 1993;9:157-65.




Back to content | Back to main menu